louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05223712: Artificial Intelligence System for the Detection and Prediction of Kidney Diseases Using Ocular Information
Official title: Artificial Intelligence System for the Detection and Prediction of Kidney Diseases Using Ocular Information
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Artificial Intelligence
Ophthalmology
Kidney Diseases
Keywords: Kidney Diseases
Artificial Intelligence
Eye information
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
Collaborators: name: First Affiliated Hospital, Sun Yat-Sen University
First posted: 2022-02-04
Enrollment: 4000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: Participants who had slit-lamp, retinal fundus photography and kidney disease tests at the Department of Nephrology, First Affiliated Hospital of Sun Yat-sen University and Medical Centre of Aikang Health Care, Guangzhou, China

Brief summary: This is an retrospective and prospective multicenter study to develop and validate an artificial intelligent (AI) aided diagnosis, therapeutic effect assessment model including chronic kidney disease (CKD) and dialysis patients starting from April 2009, which is based on ophthalmic examinations (e.g. retinal fundus photography, slit-lamp images, OCTA, etc.) and CKD diagnostic and therapeutic data (routine clinical evaluations and laboratory data), to provide a reliable basis and guideline for clinical diagnosis and treatment.


Eligibility criteria: Inclusion Criteria:

* Patients previously received kidney biopsy, ophthalmic examinations and routine examinations of the department of nephrology during in-hospital period with BCVA\>0.5.

Exclusion Criteria:

* Patients without retinal fundus images or kidney diseases.
* The quality of the retinal fundus images can not meet the requirement for furthur analysis.
* Severe loss of results of routine examinations of the department of nephrology.

Primary outcomes:
measure: Area under the receiver operating characteristic curve of the deep learning system
timeFrame: baseline
Secondary outcomes:
measure: Sensitivity and specificity of the deep learning system
timeFrame: baseline
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Zhongshan Ophthalmic Center, Sun Yat-sen University
state: Guangdong
Study officials:
affiliation: Zhongshan Ophthalmic Center, Sun Yat-sen University
name: Yizhi Liu, M.D., Ph.D.
role: STUDY_CHAIR
References:
Clinical trial NCT01384812: Prostaglandin E2 in Migraine Suffers Without Aura.
Official title: Headache Inducing Characteristics and Possible Changes in Cerebral Blood Flow After Administration of Prostaglandin E2 in Migraine Suffers Without Aura.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: "Migraine-like" Headache
Lead sponsor: Danish Headache Center
Sponsor class: OTHER
First posted: 2011-06-29
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: The hypothesis of this study is that Prostaglandin E2 (PGE2) induces headache and dilatation of brain vessels in migraine patients without aura.


Eligibility criteria: Inclusion Criteria:

* Patients with migraine without aura

Exclusion Criteria:

* Tension type headache more than x 3 per month
* Other forms for primary headache
* Headache 24 h before the day of the investigation
* Migraine 48 h before the day of the investigation
* Hypertension
* Hypotension
* Pregnant/nursing
* Daily intake of medication (except oral contraceptives and migraine rescue medicine during migraine attack)
* Cardiovascular or central nervous system (CNS) disease
* Drug/alcohol abuse
* Psychiatric disease
* Asthma or any other lung diseases

Primary outcomes:
measure: Headache score on a 10-point verbal rating scale (VRS).
timeFrame: 24 h
Secondary outcomes:
measure: Blood flow velocity in the middle cerebral artery (VMCA) measured by a Transcranial Doppler (TCD) ultrasonography (2MHz).
timeFrame: 90 min
measure: Diameter of superficial temporal artery and radial artery measured by a high resolution ultrasound scanner, C-scan.
timeFrame: 90 min
measure: Mean arterial blood pressure (MAP).
timeFrame: 90 min
measure: Electrocardiography (ECG).
timeFrame: 90 min
measure: Heart rate (HR).
timeFrame: 90 min
measure: End-tidal partial pressure of pCO2 (PetCO2).
timeFrame: 90 min
measure: Transcutaneous arterial oxygen saturation (SAT)
timeFrame: 90 min
Other outcomes:
Locations:
city: Glostrup
country: Denmark
facility: Danish Headache Center
Study officials:
affiliation: Danish Headache Center
name: Troels Wienecke, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00632112: A Real Life Evaluation of the Performance of a Large Volume Nebulizer
Official title: A Real Life Evaluation of the Performance of a Large Volume Nebulizer
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Asthma
Keywords: large volume nebulizer
Lead sponsor: Arkansas Children's Hospital Research Institute
Sponsor class: OTHER
Collaborators: name: S&T Medical Technologies, Inc.
First posted: 2008-03-10
Enrollment: 50
Sex: ALL
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pediatric patients admitted to the Pediatric Intensive Care Unit due to status asthmaticus, requiring continuous albuterol nebulization.

Brief summary: Continuous albuterol has become the standard of care for patients in status asthmaticus. We have previously performed an in-vitro study comparing 4 different brands of continuous nebulizers. We now want to compare the in-vitro with the in-vivo performance of the brand we use. we hypothesize that there will be no difference between in-vivo and in-vitro results.

Detailed description: There will be no intervention to the patients. Nebulizers will be used as per current policies and procedures. They will only be marked on the outside at the water level every 2 hours for the first 6 hours. Once ready to be discarded will be collected for laboratory testing Once in the laboratory, nebulizers will be weight on a precision scale without liquid, then they will be filled with normal saline to the first mark (6th hour) and re-weight. The nebulizers will be filled to next mark and re-weight until 200 mls. of total volume are achieved. Solution output will be calculated as the weight difference between the 2 hour periods.

Eligibility criteria: Inclusion Criteria:

* Pediatric patients admitted to Pediatric Intensive Care Unit due to status asthmaticus, requiring continuous albuterol nebulization.

Exclusion Criteria:

* Patients requiring invasive or non-invasive ventilation.

Primary outcomes:
measure: Nebulizer solution output
timeFrame: every 2 hours for first 6 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: Arkansas Children's Hospital
state: Arkansas
Study officials:
affiliation: University of Arkansas
name: Ariel Berlinski, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02788812: QOL in Incarcerated Inguinal Hernias: TAPP Vs Open Repair
Official title: The Comparison of the Quality of Life and Outcomes in Patient's With Incarcerated Inguinal Hernias: Laparoscopic Transabdominal Pre-peritoneal (TAPP) Versus Modified Lichtenstein Hernioplasty
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Inguinal Hernia
Lead sponsor: Sarawak General Hospital
Sponsor class: OTHER
First posted: 2016-06-02
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To determine if there is a difference in the quality of life in between patients who undergoes laparoscopic transabdominal pre-peritoneal (TAPP) or modified Lichtenstein hernioplasty

Detailed description: Patients presenting with incarcerated inguinal hernias will be randomized between open or laparoscopic repair groups. The primary outcome will be the quality of life scores. Patients will be followed-up for 12 months.

Eligibility criteria: Inclusion Criteria:

* 18 years of age and older
* Both genders
* Unilateral inguinal hernias
* Incarcerated inguinal hernias
* Elective setting

Exclusion Criteria:

* Anaesthesiologists) Grade \> 2
* Recurrence
* Inguinal-scrotal hernias
* Prostatectomy, Pfannenstiel incision, previous pre-peritoneal surgery
* Pregnancy
* Refusal for general anaesthesia

Primary outcomes:
measure: Quality of life scores as measured by Carolinas Comfort Scale
timeFrame: 12 months
Secondary outcomes:
measure: Operating Time in Minutes
timeFrame: 12 months
measure: Duration of Hospitalization in Days
timeFrame: 12 months
measure: Recurrence of Hernia after Operation
timeFrame: 12 monthts
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06274112: Using TMS to Understand Neural Processes of Social Motivation
Official title: Personalized Neuromodulation Targeting Dysregulated Motivational Responses Underlying Social Avoidance Behavior
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Social Avoidant Behavior
Major Depressive Disorder
Social Anxiety Disorder
Lead sponsor: Auburn University
Sponsor class: OTHER
First posted: 2024-02-23
Enrollment: 40
Sex: ALL
Minimum age (years): 25
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: All participants will receive each dose of TMS in a counterbalanced order (AB or BA)
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to use transcranial magnetic stimulation (TMS) to better understand the neural circuits associated with social motivation.

Participant includes four study visits each that range from 1.5 - 3.0 hours in duration over approximately a one month period. The first study visit involves answering survey questions, a clinical interview, and computer tasks. The second study visit involves a magnetic resonance imaging (MRI) scan, computer tasks, and a brief TMS protocol. The second and third study visits involve a full session of TMS followed by an MRI scan and computer tasks.

Adults in the Auburn/Apelika area who avoid social situations, experience symptoms of depression or social anxiety, and are between 25 years old and 50 years old are eligible to participate.


Eligibility criteria: Inclusion Criteria:

* A diagnosis of Major Depressive Disorder OR a diagnosis of Social Anxiety Disorder (assessed/confirmed at screening visit).
* Scoring above clinical threshold on a measure of social avoidant behavior (assessed/confirmed at screening visit).

Exclusion Criteria:

* Unstable medication regimen (i.e., changes in medication or dosage in past 3 months).
* Current or lifetime diagnosis of Bipolar Disorder.
* A diagnosis of substance use disorder within past 12 months.
* A diagnosis of psychotic-spectrum disorder such as Schizophrenia.
* Pregnancy or probable pregnancy.
* Medical illness or medical treatment that would preclude or inhibit study participation.
* Neurological disorder or prior neurosurgical procedure.
* History of seizures or head trauma.
* Metal implants or objects within body (e.g., pacemaker).

Primary outcomes:
measure: Social motivation
timeFrame: Immediately post-intervention
measure: Neural circuit function
timeFrame: Immediately post-intervention
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03213912: EC50 of Anesthetics During Microelectric Recording
Official title: Determination of EC50 of Anesthetics During Microelectric Recording in Patients Receiving Deep Brain Stimulation Under Anesthesia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Deep Brain Stimulation
Keywords: effective concentration
Lead sponsor: Taipei Veterans General Hospital, Taiwan
Sponsor class: OTHER_GOV
First posted: 2017-07-11
Enrollment: 23
Sex: ALL
Minimum age (years): 20
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients, aged 20-85, with clinical diagnosis of Parkinson's disease, who are undergoing deep brain stimulation for which gnenral anesthesia with endotracheal intubation is required.

Brief summary: The investigators determine the half maximum effective concentration (EC50) of the Cet value of propofol in target-controlled infusion (TCI) when co-administered with dexmedetomidine for the maintenance of general anesthesia during microelectrode recording in the deep brain surgery in patients with Parkinson's disease.

Detailed description: General anesthesia is sometimes required for DBS (deep brain stimulation) surgery in those with excessive fear, anxiety, reduced cooperation, or severe movements due to ' off drug' state. Dexmedetomidine and propofol are both used individually in the sedation for DBS surgery, and were reported to affect the MER (microelectrode recording) to some extent, especially in the higher zone of the dose range. In this study, the investigators plan to use the combination of dexmedetomidine and propofol for the maintenance of general anesthesia in patients with Parkinson's disease. In this study, dexmedetomidine is given with a loading dose of 0.5 mcg/Kg, and continuous infusion with the dose of 0.4 mcg/Kg/hr. Propofol is given within 0.8\~1.8 mcg/Kg during the MER recording (based on institutional guideline). MER recording will be observed and correlated wtih the dose of propofol. The Dixon "up-and-down" sequential allocation method was used to determine the EC50 of the value of Cet of propofol. The study aims to determine the dose that is adequate for maintaining general anesthesia with endotracheal intubation and least interference with the MER recording.

Eligibility criteria: Inclusion Criteria:

1. Aged 20-85
2. Clinical diagnosis of Parkinson's disease
3. Scheduled for deep brain stimulation surgery under general anesthesia

Exclusion Criteria:

1. Allergic history to dexmedetomidine and propofol
2. Clinical diagnosis of congestive heart failure
3. Clinical diagnosis of liver cirrhosis
4. Clinical diagnosis of third degree A-V block

Primary outcomes:
measure: Cet of propofol
timeFrame: Intraoperative
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Taipei Veterans General Hospital
Study officials:
affiliation: Taipei Veterans General Hospital, Taiwan
name: WT Change, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00039312: Comparison of Screening Tests in Detecting Cervical Neoplasia
Official title: Multi-Institutional Prospective Cohort Study For The Comparison Of Different Primary Screening Strategies For The Detection Of Cervical Neoplasia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cervical Cancer
Keywords: cervical cancer
Lead sponsor: Jonsson Comprehensive Cancer Center
Sponsor class: OTHER
First posted: 2003-01-27
Enrollment: 15
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: SCREENING

Brief summary: RATIONALE: Screening tests may help doctors detect abnormal cells in the cervix early and plan effective treatment.

PURPOSE: Screening trial to compare different types of screening tests used to detect cervical neoplasia.

Detailed description: OBJECTIVES:

* Compare the sensitivity and specificity of primary screening strategies for the detection of cervical intraepithelial or invasive neoplasia.
* Compare the positive and negative predictive values of these strategies.

OUTLINE: This is a multicenter study. Patients are stratified according to the reason for the visit (general gynecological screening vs colposcopy referral).

* Stratum 1 (general gynecological screening): Patients undergo Pap smear, visual inspection aided by acetic acid (VIA), a colposcopy, and finally a visual inspection aided by toluidine blue (VIT) followed by an acetic acid wash. A biopsy may be performed at this initial visit. Within 2-3 weeks, patients are notified of results.
* Stratum 2 (colposcopy referral): Patients undergo Pap smear, VIA, colposcopy, VIT, and possible biopsy as in stratum 1. During the same visit, patients receive histologic evaluation and treatment with See-and-Treat loop electrosurgical excision procedure and/or endocervical curettage.

PROJECTED ACCRUAL: A total of 600-1,000 patients (300-500 per stratum) will be accrued for this study.

Eligibility criteria: Inclusion Criteria::

* History of cervical neoplasia
* Presenting for a well-woman visit, annual Pap smear, or family planning

  * Other gynecological or non-gynecological complaints allowed OR
* Referred for colposcopy secondary to an abnormal Pap smear
* Planned screening for cervical cancer
* Over 18 years of age
* Prior laser surgery, cryotherapy, or conization or loop electrosurgical excision procedure for cervical neoplasia allowed

Exclusion Criteria:

* bleeding diathesis
* pregnant
* prior hysterectomy
* concurrent anticoagulants

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Jonsson Comprehensive Cancer Center, UCLA
state: California
Study officials:
affiliation: Jonsson Comprehensive Cancer Center
name: Christine Holschneider, MD
role: STUDY_CHAIR
References:
Clinical trial NCT00772512: A Study Of The Effect Of PF-04802540 On Sleep Measures
Official title: Subject- And Investigator-Blinded, Sponsor-Open, Randomized, Single-Dose, Placebo-Controlled, 3-Way Crossover Study To Study Effects Of PF-04802540 On Polysomnography Endpoints In Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: PF-04802540, polysomnography, REM, cross over
Lead sponsor: Taisho Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2008-10-15
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to determine if PF-04802540 decreases REM sleep.


Eligibility criteria: Inclusion Criteria:

* Healthy male and/or female (nonchildbearing potential) subjects between the ages of 18 and 55 years, inclusive
* Body Mass Index (BMI) between 18 to 32 kg/m2, inclusive, and a total body weight \>45 kg (99 lbs)
* Non-users of nicotine

Exclusion Criteria:

* Evidence or history of clinically significant medical illness
* A history of seizures, including childhood febrile seizures
* Any condition possibly affecting drug absorption

Primary outcomes:
measure: REM sleep percentage
timeFrame: 1 day
Secondary outcomes:
measure: REM sleep latency
timeFrame: 1 day
measure: Beta EEG power
timeFrame: 1 day
measure: Plasma concentrations of PF-04802540 and its metabolite, PF-04831035
timeFrame: 2 days
Other outcomes:
Locations:
city: New York
country: United States
facility: Pfizer Investigational Site
state: New York
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT03259412: Effect of Combined Fatty Acid Supplementation and Eccentric Exercise Training on Exercise Performance
Official title: Effect of Combined Fatty Acid Supplementation and Eccentric Exercise Training on Exercise Performance, Inflammation, Gene Expression and Epigenetic Signatures
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Exercise-induced Inflammation
Lead sponsor: Loughborough University
Sponsor class: OTHER
First posted: 2017-08-23
Enrollment: 18
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The aim of the study is to determine whether fish oil (specifically omega-3 long chain polyunsaturated fatty acids \[EPA-DHA\]) supplementation can enhance eccentric resistance exercise performance when combined with a resistance exercise training study. The investigators aim to establish the potential mechanisms that might mediate performance changes at a cellular level.


Eligibility criteria: Inclusion Criteria:

* Males
* Healthy

Exclusion Criteria:

* Resistance exercise training within the past 6 months
* Vitamin or fish oil supplementation over the past 6 months
* Habitual use of anti-inflammatory drugs
* History of heart disease
* History of coagulation/bleeding disorder
* History of metabolic disease
* Serious allergy
* Known to have blood-borne virus
* Females (Due to differences in cell membrane incorporation of Omega-3 between the sexes and the testing schedule being unable to fit in with menstrual cycle, altering the blood markers that are being measured)
* Currently no symptoms of general illness

Primary outcomes:
measure: Strength
timeFrame: Change from baseline strength at 11 weeks
measure: Leg power
timeFrame: Change from baseline strength at 11 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Leicester
country: United Kingdom
facility: Loughborough University
Study officials:
affiliation: Loughborough University
name: Lynsey S Wilson, MSc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00529412: Bioresorbable Membrane to Reduce Postoperative Small Bowel Obstruction
Official title: Bioresorbable Membrane to Reduce Postoperative Small Bowel Obstruction in Patients With Gastric Cancer. A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Gastric Cancer
Lead sponsor: Nihon University
Sponsor class: OTHER
First posted: 2007-09-14
Enrollment: 150
Sex: ALL
Maximum age (years): 79
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To assess whether the use of Seprafilm reduces the rate of small bowel obstruction in patients who underwent surgery for gastric cancer.

Detailed description: Patients with gastric cancer who were scheduled to undergo gastrectomy were randomly assigned to a sodium hyaluronate-based bioresorbable membrane (Seprafilm) group or to a control group. Before closing the abdominal incision, two sheets of Seprafilm membrane were applied to the surface of the small intestine under the middle abdominal wound in the Seprafilm group. The primary end point was the incidence of bowel obstruction. Secondary end points were intraoperative and postoperative morbidity and mortality.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of gastric cancer
* Operable

Exclusion Criteria:

* Withdrew consent
* Pregnant
* Ascites
* Distant metastasis
* Liver dysfunction (serum total bilirubin \>2.0 mg/dL)
* Renal failure (serum creatinine \>1.5 mg/dL)
* A past history of small bowel obstruction.

Primary outcomes:
measure: incidence of small bowel obstruction
timeFrame: 3 years, more than 6 months after gastrectomy
Secondary outcomes:
measure: intraoperative and postoperative morbidity and mortality.
timeFrame: 3 years
Other outcomes:
Locations:
city: Tokyo
country: Japan
facility: Department of Digestive Surgery, NIhon University School of Medicine
Study officials:
affiliation: Department of Digestive Surgery, Nihon University School of Medicine
name: Tadatoshi Takayama, MD, PhD
role: STUDY_CHAIR
References:
citation: Hayashi S, Takayama T, Masuda H, Kochi M, Ishii Y, Matsuda M, Yamagata M, Fujii M. Bioresorbable membrane to reduce postoperative small bowel obstruction in patients with gastric cancer: a randomized clinical trial. Ann Surg. 2008 May;247(5):766-70. doi: 10.1097/SLA.0b013e3181656d4e.